{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:07:42Z","timestamp":1790276862581,"version":"4.1.0"},"reference-count":8,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1016\/j.transproceed.2009.06.040","type":"journal-article","created":{"date-parts":[[2009,8,27]],"date-time":"2009-08-27T08:52:06Z","timestamp":1251363126000},"page":"2332-2333","source":"Crossref","is-referenced-by-count":15,"title":["Everolimus Represents an Advance in Immunosuppression for Patients Who Have Developed Cancer After Renal Transplantation"],"prefix":"10.1016","volume":"41","author":[{"given":"E.","family":"Gonz\u00e1lez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Andr\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Polanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Huerta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Ortu\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Guti\u00e9rrez Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Praga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2009.06.040_bib1","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/ndt\/16.8.1545","article-title":"Causes of death after renal transplantation","volume":"16","author":"Briggs","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transproceed.2009.06.040_bib2","year":"2006","journal-title":"Australia and New Zealand Dialysis and Transplant Registry"},{"key":"10.1016\/j.transproceed.2009.06.040_bib3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.critrevonc.2004.11.010","article-title":"Cancer incidence after immunosuppressive treatment following kidney transplantation","volume":"56","author":"Andres","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.transproceed.2009.06.040_bib4","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1432-2277.2006.00330.x","article-title":"Posttransplant de novo malignancies in renal transplant recipients: the past and present","volume":"19","author":"Kauffman","year":"2006","journal-title":"Transpl Int"},{"key":"10.1016\/j.transproceed.2009.06.040_bib5","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1600-6143.2004.00450.x","article-title":"Cancer after kidney transplantation in the United States","volume":"4","author":"Kasiske","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2009.06.040_bib6","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1399-0012.2004.00188.x","article-title":"Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies","volume":"18","author":"Mathew","year":"2004","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2009.06.040_bib7","unstructured":"Morales JM, Campistosl JM, Kreis H, et al: Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients. Abstract 775. American Transplant Congress, Washington, DC, May 30\u2013June 4, 2003"},{"key":"10.1016\/j.transproceed.2009.06.040_bib8","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/01.TP.0000184006.43152.8D","article-title":"Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignances","volume":"80","author":"Kauffman","year":"2005","journal-title":"Transplantation"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134509007714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134509007714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T15:56:24Z","timestamp":1545062184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134509007714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":8,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["S0041134509007714"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2009.06.040","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}